CombinatoRx Abstract Accepted for Oral Presentation at ACR 2009.-- Synavive[TM] (CRx-102) Phase 2 Extension Clinical Trial 3-12 Month Results to be Presented -- CAMBRIDGE, Mass. -- CombinatoRx, Incorporated (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRXX) today announced that its abstract entitled, "CRx-102 (Prednisolone/Dipyridamole Combination) Enhances Glucocorticoid glucocorticoid /glu·co·cor·ti·coid/ (-kor´ti-koid) 1. any of the group of corticosteroids predominantly involved in carbohydrate metabolism, and also in fat and protein metabolism and many other activities (e.g. (GC) Efficacy and Reduces Adverse Effects in OA Therapy: 3-12 Month Results", has been accepted for oral presentation at the American College of Rheumatology rheumatology /rheu·ma·tol·o·gy/ (-tol´ah-je) the branch of medicine dealing with rheumatic disorders, their causes, pathology, diagnosis, treatment, etc. rheu·ma·tol·o·gy n. (ACR See riser card. ) 2009 Annual Meeting in Philadelphia on October 20, 2009. The abstract can be accessed online at http://www.rheumatology.org/annual/index.aspwww.eular.org by clicking on "search abstracts" and entering the author name or abstract number. Oral Presentation: * Abstract #1943: "CRx-102 (Prednisolone/Dipyridamole Combination) Enhances Glucocorticoid (GC) Efficacy and Reduces Adverse Effects in OA Therapy: 3-12 Month Results," Huttner, et.al, Tuesday, October 20, 2009: 5:15 PM Room 108 B, Pennsylvania Convention Center The Pennsylvania Convention Center is a multi-use public facility in Philadelphia, Pennsylvania which is designed to accommodate conventions, exhibitions, conferences and other events. . About CombinatoRx CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action, striking at the biological complexities of human disease. The CombinatoRx proprietary drug discovery technology provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx, please visit www.combinatorx.com. Forward-Looking Statement forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. : This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 concerning CombinatoRx and its Synavive product candidate. These forward-looking statements about future expectations, plans and prospects of CombinatoRx, and its Synavive product candidate involve significant risks, uncertainties and assumptions, including risks related to CombinatoRx's ability to further develop and obtain regulatory approval for the sale of Synavive and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. These forward looking statements reflect management's current views and CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release. (c) 2009 CombinatoRx, Incorporated. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion